复宏汉霖(02696.HK)：HLX79联合汉利康®治疗活动期肾小球肾炎的2期临床研究于中国境内完成首例患者给药

Group 1 - The company Fuhong Hanlin (02696.HK) announced the completion of the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanlikang® (Rituximab injection) for the treatment of active glomerulonephritis in mainland China, excluding Hong Kong, Macau, and Taiwan [1]